Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This study will determine the tissue penetration of ceftolozane/tazobactam (Zerbaxa, Merck &
Co.), a novel β-lactam/β-lactamase combination antibiotic, into the extracellular,
interstitial fluid of soft tissue in diabetic patients with lower limb wound infections.
Penetration will be compared with a group of healthy volunteer control participants.
Phase:
Phase 1
Details
Lead Sponsor:
Hartford Hospital
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Ceftolozane Ceftolozane, tazobactam drug combination Cephalosporins Penicillanic Acid Tazobactam